These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26581795)

  • 21. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
    Vlassenko AG; McCue L; Jasielec MS; Su Y; Gordon BA; Xiong C; Holtzman DM; Benzinger TL; Morris JC; Fagan AM
    Ann Neurol; 2016 Sep; 80(3):379-87. PubMed ID: 27398953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pittsburgh compound B-negative dementia: a possibility of misdiagnosis of patients with non-alzheimer disease-type dementia as having AD.
    Shimada H; Ataka S; Takeuchi J; Mori H; Wada Y; Watanabe Y; Miki T
    J Geriatr Psychiatry Neurol; 2011 Sep; 24(3):123-6. PubMed ID: 21750305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
    Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study.
    Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Kosaka J; Kudo T; Iida H; Kishimoto T; Nagatsuka K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):920-8. PubMed ID: 26766490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Fagan AM; Mintun MA; Mach RH; Lee SY; Dence CS; Shah AR; LaRossa GN; Spinner ML; Klunk WE; Mathis CA; DeKosky ST; Morris JC; Holtzman DM
    Ann Neurol; 2006 Mar; 59(3):512-9. PubMed ID: 16372280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study.
    Degerman Gunnarsson M; Lindau M; Wall A; Blennow K; Darreh-Shori T; Basu S; Nordberg A; Larsson A; Lannfelt L; Basun H; Kilander L
    Dement Geriatr Cogn Disord; 2010; 29(3):204-12. PubMed ID: 20332638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.
    Boada M; Anaya F; Ortiz P; Olazarán J; Shua-Haim JR; Obisesan TO; Hernández I; Muñoz J; Buendia M; Alegret M; Lafuente A; Tárraga L; Núñez L; Torres M; Grifols JR; Ferrer I; Lopez OL; Páez A
    J Alzheimers Dis; 2017; 56(1):129-143. PubMed ID: 27911295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
    Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM
    Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ellis KA; Darby D; Ames D; Harrington K; Martins RN; Masters CL; Szoeke C; Savage G; Villemagne VL; Rowe CC;
    Alzheimers Dement; 2014 Nov; 10(6):743-751.e1. PubMed ID: 24589436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
    Rembach A; Watt AD; Wilson WJ; Villemagne VL; Burnham SC; Ellis KA; Maruff P; Ames D; Rowe CC; Macaulay SL; Bush AI; Martins RN; Masters CL; Doecke JD;
    J Alzheimers Dis; 2014; 40(1):95-104. PubMed ID: 24334723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
    Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers.
    Schultz AP; Kloet RW; Sohrabi HR; van der Weerd L; van Rooden S; Wermer MJH; Moursel LG; Yaqub M; van Berckel BNM; Chatterjee P; Gardener SL; Taddei K; Fagan AM; Benzinger TL; Morris JC; Sperling R; Johnson K; Bateman RJ; ; Gurol ME; van Buchem MA; Martins R; Chhatwal JP; Greenberg SM
    Ann Neurol; 2019 Oct; 86(4):616-625. PubMed ID: 31361916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
    JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physical activity attenuates age-related biomarker alterations in preclinical AD.
    Okonkwo OC; Schultz SA; Oh JM; Larson J; Edwards D; Cook D; Koscik R; Gallagher CL; Dowling NM; Carlsson CM; Bendlin BB; LaRue A; Rowley HA; Christian BT; Asthana S; Hermann BP; Johnson SC; Sager MA
    Neurology; 2014 Nov; 83(19):1753-60. PubMed ID: 25298312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.